Viral transduction for T cell engineering in immunotherapy

Viral transduction of primary T cells enables stable genetic engineering for research and immunotherapy, supporting both transgene overexpression and gene deletion. Although the overall workflow can be similar to transduction in other mammalian cell lines, primary T cell culture imposes distinct requirements such as cell-state-dependent nuances shaped by T cell activation and proliferation, which can make it challenging to obtain a sufficient number of genetically engineered T cells. This article provides practical guidance for researchers new to T cells but familiar with basic mammalian cell culture.